Theramine Plus

Drug overview for THERAMINE PLUS (choline bitartrate/aa no.10/gaba/herb #129/protein/soy lecit):

Generic name: CHOLINE BITARTRATE/AA NO.10/GABA/HERB #129/PROTEIN/SOY LECIT
Drug class:
Therapeutic class: Alternative Therapy

No enhanced Introduction information available for this drug.

No enhanced Uses information available for this drug.

DRUG IMAGES

No Image Available

The following indications for THERAMINE PLUS (choline bitartrate/aa no.10/gaba/herb #129/protein/soy lecit) have been approved by the FDA:

Indications:
None.

Professional Synonyms:
None.

The following drug interaction information is available for THERAMINE PLUS (choline bitartrate/aa no.10/gaba/herb #129/protein/soy lecit):

Contraindicated
Severe
Moderate

There are 0 contraindications.

There are 2 severe interactions. These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.

Drug Interaction	Drug Names
Exagamglogene Autotemcel/Disease Modifying Agents SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The interaction potential of disease modifying agents with exagamglogene autotemcel is unknown.(1) CLINICAL EFFECTS: Disease modifying agents may interfere with exagamglogene autotemcel therapy.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discontinue disease modifying therapies for sickle cell disease (e.g. voxelotor, crizanlizumab) at least 8 weeks prior to the start of mobilization.(1) It is recommended that patients be transfused at least 8 weeks prior to the initiation of myeloablative conditioning. At initiation of red blood cell exchange or simple transfusions, discontinue disease modifying therapies for sickle cell disease (e.g. voxelotor, crizanlizumab).(1) DISCUSSION: There is no experience with the use of disease modifying agents with exagamglogene autotemcel infusion.(1)	CASGEVY
Lovotibeglogene Autotemcel/Disease Modifying Agents SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The interaction potential of disease modifying agents with lovotibeglogene autotemcel is unknown.(1) CLINICAL EFFECTS: Disease modifying agents may interfere with lovotibeglogene autotemcel therapy.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discontinue disease modifying therapies (e.g. voxelotor, crizanlizumab) for sickle cell disease at least 8 weeks prior to start of mobilization and conditioning.(1) DISCUSSION: There is no experience with the use of disease modifying agents with lovotibeglogene autotemcel infusion.(1)	LYFGENIA

Drug Interaction

Drug Names

Exagamglogene Autotemcel/Disease Modifying Agents

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: The interaction potential of disease modifying agents with exagamglogene autotemcel is unknown.(1)

CLINICAL EFFECTS: Disease modifying agents may interfere with exagamglogene autotemcel therapy.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Discontinue disease modifying therapies for sickle cell disease (e.g. voxelotor, crizanlizumab) at least 8 weeks prior to the start of mobilization.(1) It is recommended that patients be transfused at least 8 weeks prior to the initiation of myeloablative conditioning. At initiation of red blood cell exchange or simple transfusions, discontinue disease modifying therapies for sickle cell disease (e.g. voxelotor, crizanlizumab).(1)

DISCUSSION: There is no experience with the use of disease modifying agents with exagamglogene autotemcel infusion.(1)

CASGEVY

Lovotibeglogene Autotemcel/Disease Modifying Agents

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: The interaction potential of disease modifying agents with lovotibeglogene autotemcel is unknown.(1)

CLINICAL EFFECTS: Disease modifying agents may interfere with lovotibeglogene autotemcel therapy.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Discontinue disease modifying therapies (e.g. voxelotor, crizanlizumab) for sickle cell disease at least 8 weeks prior to start of mobilization and conditioning.(1)

DISCUSSION: There is no experience with the use of disease modifying agents with lovotibeglogene autotemcel infusion.(1)

LYFGENIA

There are 0 moderate interactions.

Moderate List
Maple syrup urine disease

The following precautions are available for THERAMINE PLUS (choline bitartrate/aa no.10/gaba/herb #129/protein/soy lecit):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

No enhanced Pregnancy information available for this drug.

No enhanced Lactation information available for this drug.

No enhanced Geriatric Use information available for this drug.